Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dose-finding trial

Journal of Clinical Oncology

Volumn 20, Issue 11, 2002, Pages 2610-2615

  Hwu, Wen Jen ^a   Krown, Susan E ^a   Panageas, Katherine S ^a   Menell, Jennifer H ^a   Chapman, Paul B ^a   Livingston, Philip O ^a   Williams, Linda J ^a   Quinn, Carolyn J ^a   Houghton, Alan N ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE; THALIDOMIDE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BRAIN METASTASIS; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DEEP VEIN THROMBOSIS; DIARRHEA; DOSE CALCULATION; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HUMAN; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME; VISUAL IMPAIRMENT;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; SURVIVAL RATE; THALIDOMIDE;

EID: 0036605798     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.09.034     Document Type: Article

References (26)

1. Dacarbazine-based chemotherapy for metastatic melanoma: Thirty-year experience overview
2. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b
3. Randomized trial of treatment with cisplatin, and interleukin-2 either alone or in combination with interferon alfa-2a in patients with metastatic melanoma
4. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
5. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse
6. Cerebrospinal fluid levels of temozolomide as a surrogate marker for brain penetration
7. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma
8. Thalidomide is an inhibitor of angiogenesis
9. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade
10. Thalidomide selectivity inhibits tumor necrosis factor alpha production by stimulated human monocytes
11. The immunosuppressive drug thalidomide induced T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen-and antigen-stimulated human peripheral blood mononuclear cell cultures
12. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset
13. Current status of thalidomide in the treatment of cancer
14. Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer
15. Phase I trial of temozolomide using an extended continuous oral schedule
16. Angiogenesis in cancer, vascular, rheumatoid, and other disease
17. A phase II study of temozolomide for recurrent brain metastases
18. Three-arm phase II study of temozolomide (TMZ) in metastatic melanoma (MM): Preliminary results
19. Phase II study of outpatient bio-chemotherapy with temozolomide, for metastatic melanoma: BRUOG MEL 69
20. Phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide (CVT), interleukin-2 (IL-2) and interferona-2b (IFN) in patients with metastatic melanoma
21. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma
22. Persistent and marked inactivation of O6-alkylguanine-DNA alkyltransferase (AGAT), a mechanism of resistance to alkylator, with protracted low-dose oral schedules of temozolomide
23. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
24. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents